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gust 28, 2013.he aim of this study was to assess the pattern of the adoption of internal mammary artery (IMA) grafting in the
United States, test its association with clinical outcomes, and assess whether its effectiveness differs in key clinical
subgroups.Background The effect of IMA grafting on major clinical outcomes has never been tested in a large randomized trial, yet it is now
a quality standard for coronary artery bypass graft (CABG) surgery.Methods We identiﬁed Medicare beneﬁciaries 66 years of age who underwent isolated multivessel CABG between 1988
and 2008, and we documented patterns of IMA use over time. We used a multivariable propensity score to match
patients with and without an IMA and compared rates of death, myocardial infarction (MI), and repeat
revascularization. We tested for variations in IMA effectiveness with treatment  covariate interaction tests.Results The IMA use in CABG rose slowly from 31% in 1988 to 91% in 2008, with persistent wide geographic variations.
Among 60,896 propensity score-matched patients over a median 6.8-year follow-up, IMA use was associated with
lower all-cause mortality (adjusted hazard ratio: 0.77, p < 0.001), lower death or MI (adjusted hazard ratio: 0.77,
p < 0.001), and fewer repeat revascularizations over 5 years (8% vs. 9%, p < 0.001). The association between IMA
use and lower mortality was signiﬁcantly weaker (p  0.008) for older patients, women, and patients with diabetes
or peripheral arterial disease.Conclusions Internal mammary artery grafting was adopted slowly and still shows substantial geographic variation. IMA use is
associated with lower rates of death, MI, and repeat coronary revascularization. (J Am Coll Cardiol 2014;63:33–9)
ª 2014 by the American College of Cardiology FoundationCoronary artery bypass graft (CABG) surgery was generally
performed with saphenous veins as conduits until the
pivotal study of Loop et al. (1) reported improved long-term
outcomes from using the internal mammary artery (IMA) as
a conduit. Their single-center, nonrandomized comparison
of 5,931 patients reported a 38% reduction in the risk
of death over 10 years of follow-up from use of the IMA.
Similar results were subsequently reported by others with
observational data (2–5). The only randomized trial of IMA
grafting enrolled just 80 patients and lacked statisticall of Medicine, Stanford, California; yNational
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; revised manuscript received August 27, 2013,power to assess its effect on hard cardiac outcomes (6).
Perhaps because there has never been a large, deﬁnitive
randomized trial, adoption of IMA grafting has been slow
and uneven in the United States (7–11). The National
Quality Forum in 2004 adopted use of an IMA graft as
a measure of the quality of CABG (12), which is now re-
ported publicly by several states. In this study, we sought to
document the patterns of adoption of IMA use in coronary
revascularization procedures performed in Medicare beneﬁ-
ciaries and assess the association of IMA grafting with
long-term outcomes in a “real-world” population of patients
undergoing CABG.Methods
The overall study population consisted of Medicare beneﬁ-
ciaries who underwent CABG between 1988 and 2008 who
were included in the 20% sample of Part A data. We
identiﬁed patients with the International Classiﬁcation of
Abbreviations
and Acronyms
CABG = coronary artery
bypass graft surgery
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
ICD9-CM = International
Classiﬁcation of Diseases,
Ninth Revision-Clinical
Modiﬁcation
IMA = internal mammary
artery
MI = myocardial infarction
PAD = peripheral arterial
disease
PCI = percutaneous coronary
intervention
pint = p value for the
treatment  covariate
interaction test
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34Diseases, Ninth Revision, Clin-
ical Modiﬁcation (ICD9-CM)
procedure codes for multivessel
CABG (36.12, 36.13, 36.14,
36.16, or 36.11 plus 36.15) and
identiﬁed IMA grafts by proce-
dure codes 36.15 or 36.16.
We excluded patients who had
single-vessel CABG, concomitant
cardiac procedures (such as valve
replacement) at the time of CABG,
evidence of a prior coronary revas-
cularization (a Medicare hospital
stay for CABG or percutaneous
coronary intervention [PCI] since
1988 or a prior condition code
of V.15.1, V45.81, or V45.82 in
the index admission), were of
unknown race, or who had end-
stage renal disease receiving
chronic dialysis.
We used the subset of thisoverall population who received CABG between 1992 and
2008 to assess the association of IMA use with clinical
outcomes, because data on some key characteristics needed
for risk adjustment were not available before 1992. To
permit a 1-year look-back period and document the presence
of comorbid conditions, we restricted this portion of the
study population to individuals 66 years of age or older who
had both Part A and Part B Medicare coverage and who
were not enrolled in a Medicare Advantage Managed Care
Program (in which diagnosis and procedure codes are not
available) in the year before the procedure. Part B data from
1992 through 1997 were available from only a 5% sample of
beneﬁciaries rather than the 20% sample available from 1998
through 2008. We deﬁned comorbid conditions with
outpatient and inpatient encounters in the year before the
index procedure. We considered a comorbidity to be present
if it was recorded as a primary or secondary diagnosis code
on an inpatient admission or outpatient encounter.
We developed a multivariable logistic regression in the
analysis subset to identify baseline clinical factors that pre-
dicted receipt of an IMA graft and assessed the discrimi-
nation of the model with the C-statistic (13). We used the
results of this analysis to assign each patient a propensity
score indicating the probability that the individual would
receive an IMA graft. We then applied a greedy pair-
matching algorithm (14) to match each patient who did not
receive an IMA graft with another patient who did. The
algorithm ﬁrst matched patients at 7 digits of the propensity
score, then matched the remaining patients at 6 digits, and
so forth, down to a 2-digit match (i.e., to agreement of 0.01
or better). We additionally required that patients match on
the calendar year they underwent CABG (to control further
for any secular trends in outcome) and to be the same age
within 1 year.Patients were followed until death or December 31, 2008.
We identiﬁed all-cause mortality from the Medicare
Denominator ﬁle; admissions for acute myocardial
infarction (MI) in Part A data by an ICD9-CM primary
hospital discharge diagnosis code of 410.x; repeat CABG
in Part A data by ICD9-CM procedure codes 36.1x; and
PCIs by ICD9-CM procedure codes 36.01, 36.02, 36.05,
36.06, 36.07 and, after October 2005, 00.66. For the
endpoints of MI and repeat procedures, patients were
censored if they entered a Medicare Advantage Plan or lost
Part A coverage, because data on hospital stay would no
longer be available.
We described event-free survival data with the Kaplan-
Meier method (15), and we compared outcomes in the
matched population by IMA status with the Cox propor-
tional hazards model. We initially performed the compar-
ison among the propensity score-matched cohort without
additional adjustment for baseline clinical characteristics,
and we subsequently adjusted for the baseline characteristics
shown in Table 1, because they might provide additional
prognostic information. We tested for interactions among
each of 4 pre-speciﬁed clinical characteristics (age, sex,
diabetes, and peripheral arterial disease); treatment with
an IMA graft; and mortality with a model that contained
treatment, the selected covariate, and their interaction. We
repeated the interaction tests in models that contained other
baseline characteristics.
Results
A total of 374,918 patients in the study population under-
went isolated multivessel CABG between 1988 and 2008 and
260,119 (69%) patients received at least 1 IMA graft. Overall,
use of the IMA graft during CABG increased steadily over
time (Fig. 1), from 31% in 1988 to 91% in 2008. There was
an additional increase in use of the IMA after its adoption in
late 2004 as a quality measure for CABG (12) (Fig. 1). The
use of IMA grafting differed substantially among different
regions of the United States (Fig. 2), and although these
differences narrowed over time, they were still evident in
2008. Use of IMA grafts was highest among patients age 66
to 70 and lowest among patients age 86 years and
older (Fig. 3), and the difference in IMA use by age narrowed
progressively over time. By contrast, rates of IMA grafting
among women were slightly lower than among men
throughout the study period (Fig. 3).
In the subset of 186,451 patients who underwent isolated
multivessel CABG between 1992 and 2008 for which
baseline clinical data on comorbid conditions were available,
there were several signiﬁcant differences between patients
who received an IMA graft and those who did not (Table 1).
In addition to differences in age, geographic region, and
year of procedure, patients who received an IMA graft were
more often male and white but less likely to have diabetes.
In a multivariable logistic regression model, the strongest
independent predictors of receiving an IMA graft were
Table 1
Baseline Clinical Characteristics of Adults Undergoing Isolated CABG,
by Use of IMA Graft
Characteristic
All Patients* Propensity Score-Matched Patientsy
IMA
(n ¼ 151,909)
No IMA
(n ¼ 34,542)
IMA
(n ¼ 30,448)
No IMA
(n ¼ 30,448)
Age
66–70 yrs 32.1 24.0 24.5 24.7
71–75 yrs 32.5 28.5 29.3 29.4
76–80 yrs 23.7 27.5 27.6 27.6
81–85 yrs 9.9 15.8 15.3 15.1
86 yrs 1.8 4.1 3.3 3.3
Female 32.2 42.5 41.5 41.9
Race
White 92.8 91.7 92.6 91.9
Black 4.2 4.9 4.5 5.0
Other 3.0 3.3 2.9 3.2
Diabetes 36.4 33.8 34.0 34.3
Hypertension 78.4 74.0 74.4 75.0
Hyperlipidemia 30.2 23.5 23.8 24.4
Tobacco abuse 18.9 14.0 14.7 15.0
Chronic kidney disease 5.1 5.4 5.4 5.4
Peripheral arterial disease 21.4 22.9 23.0 23.2
Cerebrovascular disease 21.9 22.4 22.1 22.8
Prior MI 12.7 16.7 16.0 16.3
Heart failure 12.1 18.3 17.3 17.5
Unstable angina 38.4 39.5 38.6 38.7
Atrial ﬁbrillation 9.3 10.8 10.5 10.6
Primary diagnosis of MI 20.8 26.0 25.7 25.8
Metropolitan area 72.7 71.1 71.2 71.2
U.S. Census division
New England 4.8 2.9 2.9 2.9
Middle Atlantic 13.9 12.0 12.1 12.5
South Atlantic 21.4 22.7 22.5 22.7
East South Central 8.6 9.9 10.1 10.1
West South Central 11.0 17.4 15.9 15.9
East North Central 20.3 17.9 19.0 18.4
West North Central 8.6 7.5 7.7 7.7
Mountain 3.9 2.9 2.7 2.9
Paciﬁc 7.4 6.8 7.0 7.0
Year of procedure
1992–1995 7.9 21.8 16.4 16.4
1996–1999 17.2 23.6 24.6 24.6
2000–2002 29.0 28.3 30.6 30.6
2003–2005 26.5 17.8 19.2 19.2
2006–2008 19.4 8.5 9.2 9.2
Values are %. *All p values <0.0001, except chronic kidney disease (p ¼ 0.005) and cerebrovascular disease (p ¼ 0.02). yAll p values >0.05, except
race (p ¼ 0.005) and cerebrovascular disease (p ¼ 0.05).
CABG ¼ coronary artery bypass graft surgery; IMA ¼ internal mammary artery; MI ¼ myocardial infarction.
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35calendar year, U.S. census division, age, and sex, as well as
comorbidity measures indicating heart failure, chronic
obstructive lung disease, recent MI, and a history of sys-
temic cancer. The overall c-statistic of the propensity score
model was 0.71.
Outcomes. To examine the association of IMA grafting
with outcomes, we matched each of the 30,448 patients
who did not receive an IMA graft (88% of all patients
without an IMA graft) with a patient who did receive an
IMA graft and who underwent CABG in the same year, waswithin 1 year of age, and within 0.01 U of propensity score.
As expected from the matching process, the clinical char-
acteristics of the 2 groups were quite similar after matching
(Table 1).
Over a median follow-up of 6.8 years, there were 13,930
(46%) deaths among patients who received an IMA and
16,208 (53%) deaths among patients who did not receive an
IMA. The Kaplan-Meier survival rates at 5 years were 73%
among patients who received an IMA and 66% in those
who did not, and at 10 years, survival was 45% among
Figure 2 Geographic Variation in IMA Use
The percentage of patients with internal mammary artery (IMA) grafts used in
coronary artery bypass graft surgery in each state from 2006 to 2008 (top) is
indicated by different colors. The ﬁrst year that 80% of patients in each state had
an IMA graft (bottom) is indicated by different colors.
Figure 1 IMA Adoption, 1988 to 2008
Use of internal mammary artery (IMA) grafts in multivessel coronary artery bypass
graft surgery over time.
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36patients who received an IMA and 37% among patients
who did not (Fig. 4). The unadjusted hazard ratio (HR) for
death from any cause in the propensity score-matched
population was 0.77 (95% conﬁdence interval [CI]: 0.75 to
0.79, p < 0.001) and was essentially unchanged by further
adjustment for baseline characteristics (adjusted HR: 0.77,
95% CI: 0.75 to 0.78). The HR for the composite out-
comes of death or MI was 0.78 (95% CI: 0.76 to 0.80),
which was also virtually unchanged by further adjustment
for baseline factors (HR: 0.77, 95% CI: 0.75 to 0.79). The
rate of repeat revascularization at 5 years was signiﬁcantly
lower among surviving patients who had received an IMA
compared with those who had not received an IMA (8% vs.
9%, p < 0.001).
The 30-day mortality was slightly lower among patients
who received an IMA graft (3.8% vs. 6.4%, p < 0.001). We
next performed a secondary analysis to assess the association
of IMA grafting with long-term outcomes among patients
who survived at least 30 days after CABG. In this analysis of
28,451 patient pairs, the 5-year survival was 76% among
patients who received an IMA and 70% among patients who
did not. The unadjusted HR for death comparing IMA use
versus nonuse among 30-day survivors was 0.79 (95% CI:
0.77 to 0.81, p < 0.001) and was essentially unchanged byadditional adjustment for baseline characteristics (HR: 0.79,
95% CI: 0.77 to 0.81).
The use of an IMA graft was associated with a smaller
survival advantage among patients with diabetes (p value
for the treatment  covariate interaction test [pint] ¼ 0.001),
patients with peripheral arterial disease (pint < 0.001),
among older patients (pint < 0.001), and women (pint ¼
0.008). After additional adjustments for the baseline factors
in Table 1, the interactions remained signiﬁcant for diabetes
(pint ¼ 0.011), peripheral arterial disease (pint ¼ 0.027), and
age (pint < 0.001) but not for women (pint ¼ 0.083). Use of
an IMA graft was associated with improved survival in
all pre-speciﬁed subgroups, however, except for patients
86 years of age and older (Fig. 5).
Discussion
This study documents the slow adoption of IMA graft-
ing among Medicare beneﬁciaries undergoing isolated
multivessel CABG. In 1988, 2 years after publication of the
pivotal paper by Loop et al. (1), IMA grafts were used in
only approximately 30% of CABG procedures, and 5 years
Figure 3 IMA Adoption by Age and Sex
Use of internal mammary artery (IMA) grafts in multivessel coronary artery bypass
graft surgery over time by age (top) and sex (bottom). The growth of IMA grafting
use over time differed greatly according to age (p < 0.0001) but only slightly
according to sex (p ¼ 0.04).
Figure 4 Survival by IMA Use
Survival after multivessel coronary artery bypass graft surgery, by internal
mammary artery (IMA) use, in the propensity-matched population. The difference in
survival was signiﬁcant (p < 0.0001).
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37later this had increased only to approximately 50% of
patients. Patient-related factors were relatively weak
predictors of IMA use, apart from age. The considerable
geographic variation in IMA use and the weak predictive
power of patient characteristics in determining its use
suggest that surgical practice style was the key factor
determining adoption of IMA grafting during CABG. The
recognition of IMA grafting as a quality measure for CABG
(12,16) is likely to further increase its use and attenuate any
residual geographic variation.
The slow adoption of IMA grafting contrasts with the
rapid uptake of drug-eluting stents (DES) during PCI,
which were used in over 50% of procedures within 6 months
of approval by the Food and Drug Administration and in
90% of procedures within 2 years (17). There are several
notable differences between these 2 innovations that might
have affected their adoption. Use of a DES instead of
a bare-metal stent does not extend the time or difﬁculty of
the procedure, whereas dissection of the IMA and per-
forming the anastomosis do extend the duration and
difﬁculty of CABG. Also, there were several large
randomized trials showing that the use of DES reduced the
rate of repeat revascularization (18), but there have been no
large randomized trials of IMA grafting, so the evidence for
its efﬁcacy was weaker. Finally, DES were vigorously
promoted by the manufacturers to cardiologists, whereasthere was no concerted marketing of IMA grafts to
surgeons.
Our study conﬁrms the association of IMA grafting with
improved outcomes after CABG. The adjusted HR for
mortality of 0.77 that we observed in this study was some-
what less favorable than the HR of 0.61 reported by the
original study of Loop et al. (1), but was almost identical to
the more contemporary estimate of 0.77 derived from 3,087
patients enrolled in 8 trials of CABG and PCI (4). The
present study is much larger than any prior study of the
association of IMA grafting with outcomes, and it is based
on a representative population of older patients and their
treating surgeons in the United States. The present study is
also based on more contemporary patients than earlier
reports. We also found that, in addition to the association of
IMA graft use with lower mortality, IMA use was associated
with a lower rate of death or MI (adjusted HR: 0.78) and
with a slightly lower use of repeat coronary revascularization
procedures. These data are consistent with observations that
the IMA is more durable than a saphenous vein graft and
less likely to develop stenosis or occlusion in long-term
follow-up (19,20).
Our study was much larger than previous studies of
outcomes after IMA grafting, so we were also able to assess
outcomes in several key clinical subgroups (Fig. 5). The
association of IMA grafting with lower mortality was
strikingly modiﬁed by patient age, with a progressively less
Figure 5 IMA Effectiveness in Subgroups
Hazard ratios (95% conﬁdence interval) for mortality associated with use of an internal mammary artery (IMA) graft among pre-speciﬁed clinical subgroups.
PAD ¼ peripheral arterial disease.
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38favorable association at older ages. Indeed, our data show no
association of IMA grafting with mortality among patients
86 years of age or more (Fig. 5). The apparent effect of age
on the HR for mortality might be the result of the inherently
lower life expectancy of older patients, so there is less
opportunity for IMA grafting to improve long-term survival.
Although residual selection bias cannot be dismissed, it
seems more likely that the “healthiest” older patients would
be selected for IMA grafting, not the “sickest.” Limited life
expectancy might also explain the weaker association of
IMA grafting with survival among patients with diabetes
and peripheral arterial disease, because they also have higher
rates of mortality than patients without these conditions,
but does not explain the weaker association among women,
who generally have a longer life expectancy than men.
The 5-year survival rate in this study of patients who
received an IMA (73%) was considerably lower than the
5-year survival rate of patients assigned to CABG in
randomized trials. The 5-year survival rate was 90% after
CABG in the pooled data from 10 randomized trials
of CABG versus PCI (21) and 89% in the SYNTAX
(SYNergy Between PCI with TAXus and Cardiac Surgery)
trial (22). The better survival after CABG in these trials
than after CABG in the community is likely due to the
stringent selection of patients for the randomized trials and,
to a lesser extent, the limitation of CABG to centers ofexcellence in the trials. For instance, patients in the 10
pooled trials had a median age of 61 years, versus a median
age of 75 years in the present study. The representative
nature of the patients and providers in the present study is
a strength, and the outcomes are likely to be more repre-
sentative. The study population was, however, limited to
patients 66 years of age and older.
Use of IMAs among Medicare beneﬁciaries was 91% in
2008 but still far from universal. The reasons why IMA
grafts are not used in all contemporary CABG procedures
are uncertain. Several large registries have shown that IMA
use decreases with increasing procedural risk estimated by
multivariable scores (7,23), suggesting that surgeons might
not wish to prolong the procedure by grafting the IMA in
higher-risk cases. Operative notes contained a speciﬁc
comment in the reason for nonuse of the IMA in 53% of
cases in 1 registry (3), with the most common reasons being
damage or injury to the IMA on harvesting, poor ﬂow in the
IMA, poor lung function, and unstable symptoms. It is
likely that patients or technical factors will lead to a few
patients not receiving an IMA during CABG even when
universal use is the goal, and clinical registries could record
the reasons for nonuse of the IMA (16).
Study limitations. Our comparison of the outcomes of
patients who did and did not receive an IMA graft was based
on observational data, not a randomized trial. We did use
JACC Vol. 63, No. 1, 2014 Hlatky et al.
January 7/14, 2014:33–9 Adoption and Effectiveness of IMA in CABG
39several methods to improve comparability of the treatment
groups, starting with our restriction of the population to
patients with multivessel procedures, isolated CABG, and
no prior cardiac surgery. We matched patients on year of
procedure and on multivariable propensity score, which also
controls for potential confounding factors. The consistency
of our results in a secondary analysis of patients who survived
the ﬁrst 30 days after CABG and across multiple endpoints
is also reassuring. Nevertheless, we cannot exclude the
possibility that residual selection bias in the use of the IMA
affected our estimates of its effectiveness. This study was
based on Medicare claims and lacks data on several impor-
tant clinical variables, such as the location and extent of
coronary lesions and the level of left ventricular function. In
particular, we do not have speciﬁc information on which
patients had disease in the left anterior descending coronary
artery or where the IMA graft was placed. Although we
excluded patients who had either a Medicare claim for
cardiac surgery since 1988 or who had a condition code for
prior cardiac surgery, we cannot exclude the possibility that
some patients might have had prior CABG.
Conclusions
Our analysis conﬁrms the association of IMA grafting with
better outcomes among older patients receiving multivessel
CABG and reinforces the choice of IMA grafting as
a quality measure. The reasons for the relatively slow and
uneven adoption of IMA grafting in CABG should be
further studied to better understand the barriers to diffusion
of treatment advances.
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